Coronary artery disease (CAD) prevalence is increased and life expectancy is reduced by more than a decade in people with type 1 diabetes (T1D) compared to nondiabetics (non-DM), but traditional risk factors do not explain all of the increased risk. We examined whether three novel risk markers, high-sensitive cardiac troponin T (hs-cTnT), N-terminal pro-B-type natriuretic peptide (NT-proBNP), and growth differentiation factor 15 (GDF-15), are elevated in T1D and predict CAD and mortality.

1,416 adults age 19-56 (652 T1D, 754 non-DM) were enrolled in the Coronary Artery Calcification in type 1 diabetes (CACTI) study from 2000-2002. We assessed CAD events (fatal or non-fatal myocardial infarction, coronary artery bypass graft, or angioplasty) with annual follow-up questionnaires. In-person visits occurred at 3, 6, and 12 years after baseline. Serum samples from the visit prior to a CAD event or death or from the last in-person visit were available for 1,389 participants and were assayed for hs-cTnT, NT-proBNP, and GDF-15 at the University of Maryland. Elevated marker levels were defined as those above the 95th percentile among non-DM participants. Biomarker levels were compared by T1D status in linear regression, and logistic regression was used to examine associations with CAD and all-cause mortality.

Age- and sex-adjusted LSmeans ± SE for log hs-cTnT (2.0±0.02 vs. 1.6±0.02, p<0.0001), log NT-proBNP (3.8±0.04 vs. 3.5±0.03, p#x003C;0.0001), and log GDF-15 (6.5±0.02 vs. 6.2±0.02, p#x003C;0.0001) were significantly higher in T1D than non-DM participants. Over the follow-up period, there were 72 CAD events (53 T1D, 19 non-DM) and 76 deaths (58 T1D, 18 non-DM). Having elevated levels of all 3 vs. none of the markers was a significant predictor of both CAD (OR [95% CI] 6.4 [2.0-20.7]) and all-cause mortality (OR [95% CI] 10.7 [3.3-35.4]), independent of age, sex, renal function and T1D status.

A panel of novel markers, hs-cTnT, NT-proBNP, and GDF-15, are elevated in T1D and may help identify those at risk for CAD events and mortality.


A. Keshawarz: None. R.M. Sippl: None. H. Rebuck: None. S. Donald: None. S.Y. Huang: None. R.H. Christenson: Consultant; Self; Roche Diagnostics Corporation, Siemens, Becton, Dickinson and Company. J.K. Snell-Bergeon: Stock/Shareholder; Self; Abbott. Research Support; Self; Roche Diagnostics Corporation.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at